Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Medical Countermeasures

    Antibody’s Unusual Abilities Might Inspire Vaccine Strategies

    By Global Biodefense StaffMay 21, 2015
    E. coli Appendages Adhere to Other Cells
    E. coli bacteria showing the appendages used to adhere to other cells. For example, certain forms of E. coli can attached to human cells in the urinary tract to cause infection. Credit: Sokurenko lab/University of Washington
    Share
    Facebook LinkedIn Reddit Email

    The recent discovery of a novel antibody that works in an unusual way might inspire ideas for designing more effective vaccines.

    The antibody appears to have properties that might keep bacteria from adhering to human cell surfaces and also dislodge those already attached.

    The researchers reported on the antibody in the May 14 issue of PLOS Pathogens. Dagmara I. Kisiela, University of Washington acting instructor of microbiology, was the paper’s lead author. Evgeni V. Sokurenko, UW professor of microbiology, was the senior author.

    In the study, the researchers were looking for antibodies that go after a protein the bacteria E. coli uses to attach to human cells. This attachment is a necessary first step the bacteria must take to cause an infection.

    The researchers were particularly interested in strains of E. coli that cause urinary tract infections. Approximately half of all women and 12 percent of men will experience a urinary tract infection in their lifetime. Up to 90 percent of those infections will be caused by one of the E. coli strains that trouble the urinary tract.

    To attach to human cells, E. coli use hair-like structures, called fimbriae, on the end of which sit pocket-shaped proteins. These proteins, called adhesins, grasp and hold onto sugar-like molecules found on the surface of human cells. For many years, researchers have sought to develop a vaccine that would generate antibodies to bind to and block an adhesin called FimH.

    To set off an infection, E. coli uses FimH to attach, via the sugar mannose, to the cells that line the urinary tract and bladder wall. One vaccine showed great promise in preventing urinary tract infections in animal studies, but failed to protect sufficiently well in humans.

    Follow-up studies of the disappointing vaccine showed that antibodies generated against the FimH protein could indeed bind to the protein. However, the antibodies couldn’t disable FimH and prevent the bacteria from attaching to human cells.

    Kisiela, Sokurenko and their colleagues reasoned that previous attempts at a vaccine fell short because mannose-like molecules floating in the body fluids were occupying the FimH mannose-grasping pocket. Their occupation shielded the pocket. The immune system couldn’t detect the site and generate adequate antibodies against it. The researchers tested their hypothesis using a form of FimH with the pocket locked in an open position. This exposed the pocket to the immune system.

    The researchers found that the inactivated FimH worked by producing antibodies that bound directly to the inside of the pocket. All these antibodies appeared to work in a classical manner: the antibody essentially competes with mannose for access to the pocket. But, as the scientists had suspected, most of the antibodies were less effective if FimH is already bound to either free-floating or cell surface mannose.

    One antibody, however, appeared to work better than the others. This antibody, called Ab926, not only prevented the bacteria from attaching to mannose, but also forced the bacteria that were already attached to let go, something the other antibodies could not do. It turned out mAb926 did not bind directly into the pocket as the others did. Instead, it bound to a side of the pocket. The researcher dubbed this novel mechanism parasteric, meaning “to the side.”

    “FimH is like a three fingered hand that closes around the mannose when it binds,” Sokurenko explained. “But the pocket is dynamic and intermittently tightens and loosens its grip.” This makes sense, he continued, because the bacteria need to be able to release themselves and move if they’re to travel around the urinary tract and invade tissues.

    In the case of FimH, the loosening takes place when one of the fingers lifts away, momentarily relaxing the pocket’s grip on the mannose. What appears to happen is mAb926 binds to this finger when the pocket is in this relaxed state and prevents it from closing again. As a result, FimH is unable to hold onto the mannose and lets go.

    This parasteric action has two advantages over the classical antibody action, Kisiela said. First, unlike the other type of antibodies, this antibody does not have to compete with free-floating mannose for access to the FimH pocket. This means it should be more effective at disabling FimH before it binds to its target.

    Second, because it can also act on FimH even after bacteria has attached to bladder cells and disable its pocket whenever it relaxes its grip. This raises the possibility that this type of antibodies could be used not only to prevent infections, but also to treat established E. coli infections by loosening the bacterium’s grip so it can be flushed off the wall of the bladder and urinary tract.

    The study was done in collaboration with researchers at the Fred Hutchinson Cancer Research Center and the New York University School of Medicine.

    Read the study: Inhibition and Reversal of Microbial Attachment by an Antibody with Parasteric Activity against the FimH Adhesin of Uropathogenic E. coli.

    E. coli Vaccine News
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleDHS Awards Final Contract for National Bio and Agro-Defense Facility
    Next Article Experimental Ebola Treatment Boosts Survival in Mice

    Related Stories

    New Method Improves Quantification of Ricin in Complex Matrices

    September 20, 2023

    Jurata Thin Film and CastleVax Awarded Grant to Advance Thermostabilized COVID-19 Booster

    September 20, 2023

    Mount Sinai to Lead Development of Pan-Coronavirus Vaccine Under New Federal Grant

    September 17, 2023

    Mass Spec for Rapid Detection of Biological Warfare Agents

    September 15, 2023
    News Scan

    Biodefense Headlines – 19 September 2023

    News Scan September 19, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include a global survey of gain-of-function research; funding of an mRNA mpox vaccine; Nipah virus outbreak in India; field detection of threat agents with acoustic…

    Upcoming Events

    Oct 3
    Virtual Event Virtual Event
    October 3 - October 5

    OneLab Summit 2023

    Oct 3
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships to Distribute, Dispense, and Administer Medical Countermeasures

    Oct 4
    Virtual Event Virtual Event
    10:00 am - 2:00 pm EDT

    Tunneling Nanotubes and Intracellular Protrusions Workshop

    Oct 12
    Virtual Event Virtual Event
    12:00 pm - 2:00 pm EDT

    Public-Private Partnerships for Acceptance and Uptake of Medical Countermeasures

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.